148 related articles for article (PubMed ID: 36108259)
1. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW; Beitsch PD; Murray MK; Richards PD; Mislowsky A; Dul CL; Pellicane JV; Baron PL; Rahman RL; Lee LA; Dupree BB; Kelemen PR; Ashikari AY; Budway RJ; Lopez-Penalver C; Dooley W; Wang S; Dauer P; Menicucci AR; Yoder EB; Finn C; Blumencranz LE; Audeh W
JCO Precis Oncol; 2022 Sep; 6():e2200197. PubMed ID: 36108259
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P; Whitworth P; Baron P; Rotkis MC; Mislowsky AM; Richards PD; Murray MK; Pellicane JV; Dul CL; Nash CH; Stork-Sloots L; de Snoo F; Untch S; Lee LA
Ann Surg Oncol; 2017 Sep; 24(9):2539-2546. PubMed ID: 28447218
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Blumencranz P; Habibi M; Shivers S; Acs G; Blumencranz LE; Yoder EB; van der Baan B; Menicucci AR; Dauer P; Audeh W; Cox CE
Ann Surg Oncol; 2023 Dec; 30(13):8353-8361. PubMed ID: 37658272
[TBL] [Abstract][Full Text] [Related]
4. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV; Beitsch PD; Rock DT; Budway RJ; Dul CL; Kelemen PR; Ashikari AY; Baron PL; Weinstein PD; Mislowsky A; Lee LA; Beatty J; Murray MK; Dupree BB; Finn C; Corcoran K; Wang S; Menicucci AR; Yoder EB; Blumencranz LE; Dauer P; Audeh W; Whitworth PW;
Surg Oncol; 2022 Dec; 45():101885. PubMed ID: 36436423
[TBL] [Abstract][Full Text] [Related]
5. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.
Denkert C; Huober J; Loibl S; Prinzler J; Kronenwett R; Darb-Esfahani S; Brase JC; Solbach C; Mehta K; Fasching PA; Sinn BV; Engels K; Reinisch M; Hansmann ML; Tesch H; von Minckwitz G; Untch M
Breast Cancer Res; 2013 Feb; 15(1):R11. PubMed ID: 23391338
[TBL] [Abstract][Full Text] [Related]
6. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
[TBL] [Abstract][Full Text] [Related]
7. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
8. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
9. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
10. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
Prat A; Carey LA; Adamo B; Vidal M; Tabernero J; Cortés J; Parker JS; Perou CM; Baselga J
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139534
[TBL] [Abstract][Full Text] [Related]
11. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
12. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Whitworth PW; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Murray MK; Gittleman MA; Budway RJ; Rahman RL; Kelemen PR; Dooley WC; Rock DT; Cowan KH; Lesnikoski BA; Barone JL; Ashikari AY; Dupree BB; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
JCO Precis Oncol; 2022 Apr; 6(1):e2100463. PubMed ID: 35476550
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.
Li Y; Zhang X; Liu D; Gong J; Wang DD; Li S; Peng Z; Li Y; Wang X; Lin PP; Li M; Shen L
Clin Cancer Res; 2018 Nov; 24(21):5261-5271. PubMed ID: 30012565
[No Abstract] [Full Text] [Related]
17. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
18. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
19. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
[TBL] [Abstract][Full Text] [Related]
20. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
